Business / Finance

RSS

Nuvo Research intends to proceed with its proposed share consolidation

Nuvo Research Inc. (the "Company" or "Nuvo"), a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain and the development of its immune modulating drug candidate WF10, today announced that it will proceed with its proposed share consolidation (the "Consolidation"), as approved by the shareholders of Nuvo at the annual and special meeting held on May 15, 2012, on the basis of 65 pre-Consolidation common shares for one (1) post-Consolidation common share.

7 May 2013

Biocryst reports financial results for first quarter 2013

BioCryst Pharmaceuticals, Inc. announced financial results for the first quarter ended March 31, 2013.

7 May 2013

Akorn reports record consolidated revenue of $73.9 million in first quarter 2013

Akorn, Inc., a niche generic pharmaceutical company, today reported financial results for its first quarter ended March 31, 2013.

7 May 2013

Hospital for Special Surgery signs agreement with Brazilian healthcare organization

Clinical pathways and quality initiatives leading to world class outcomes are the foundation of a far-reaching agreement between New York-based Hospital for Special Surgery, the recognized leader in orthopedics, rheumatology and related specialties, and Amil Par, the largest managed healthcare organization in Brazil, on behalf of Hospitalys Ortopedia, its newly opened orthopedic center in Rio de Janeiro.

7 May 2013

NeuroPhage Pharmaceuticals raises $6.4 million in private equity financing round

NeuroPhage Pharmaceuticals, Inc., a company developing breakthrough therapies for neurodegenerative diseases, today announced that it raised $6.4 million in a private equity financing round.

6 May 2013

Comprehensive Care Closes $5 million Senior Secured Credit Facility with TCA

Comprehensive Care Corporation, a leading behavioral health, substance abuse and pharmacy management provider for employers, Taft-Hartley health and welfare Funds, and managed care companies, today announced that it has closed a $5 million Senior Secured Credit Facility with TCA Global Credit Master Fund (TCA).

6 May 2013

National Health Investors announces its normalized Funds From Operations

National Health Investors, Inc. announced today its normalized Funds From Operations ("FFO"), its normalized Funds Available for Distribution ("FAD") and net income attributable to common stockholders for the three months ended March 31, 2013.

6 May 2013

ApolloMed net revenues climbed 52.2% to $7.8 million during fiscal 2013

Apollo Medical Holdings, Inc., an integrated physician-driven healthcare delivery company that puts 'Patients First,' today announced its fiscal year-end results for the three and twelve months ended January 31, 2013.

5 May 2013

U.S. Department of Justice clears Aetna's proposed acquisition of Coventry Health Care

Aetna today announced the U.S. Department of Justice has cleared Aetna's proposed acquisition of Coventry Health Care, Inc. Aetna expects to complete its acquisition of Coventry within the next three business days.

4 May 2013

Regeneron Pharmaceuticals expands ophthalmology portfolio

Regeneron Pharmaceuticals, Inc. today announced that it has expanded its ophthalmology portfolio by acquiring full exclusive rights to two families of novel antibodies invented at Regeneron and previously included in Regeneron's antibody collaboration with Sanofi.

3 May 2013

Cambrex sales increase by 5.7% in first quarter 2013

Cambrex Corporation reports results for the first quarter ended March 31, 2013.

3 May 2013

BioLife Solutions licenses specific areas of intellectual property to Janssen

BioLife Solutions, Inc., a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media for cells and tissues, and contract aseptic media manufacturer, today announced that it has licensed specific areas of its intellectual property to Janssen Research & Development, LLC.

2 May 2013

RainDance Technologies announces closing of $20M Series E financing round

RainDance Technologies, Inc., the Digital Biology Company, today announced the closing of a $20 million Series E financing round. The company also announced that Myriad Genetics, Inc. has joined as a new strategic equity investor.

29 Apr 2013

Opsona raises €33M in oversubscribed financing round

Opsona Therapeutics Limited, the innate immune drug development company, today announced that it has raised €33 million (US $ 43 million) in an oversubscribed Series C financing.

29 Apr 2013

Shin Poong to develop, market Almac Discovery's ALM201 in South Korea

Almac Discovery today announced the licensing of its novel anti-angiogenic peptide ALM201 to Shin Poong Pharmaceutical Company Ltd for clinical development and marketing in South Korea.

29 Apr 2013

Simulations Plus to distribute quarterly cash dividend in May 2013

Simulations Plus, Inc., a leading provider of simulation and modeling software for pharmaceutical discovery and development, today announced that its Board of Directors has decided to distribute a cash dividend in May.

26 Apr 2013

HMS Holdings revenue increases 8.7% to $116.6M in first quarter 2013

HMS Holdings Corp. today announced financial results for its first quarter ended March 31, 2013 and provided revised 2013 guidance.

26 Apr 2013

Sectra signs agreement to distribute healthcare IT suite in Puerto Rico

International medical imaging IT company, Sectra announces an exclusive agreement with Answer Medical Solutions to distribute its healthcare IT suite throughout Puerto Rico.

26 Apr 2013

DJO Global reports first quarter results for 2013

DJO Global, Inc., a leading global provider of medical device solutions for musculoskeletal health, vascular health and pain management, today announced financial results for its public reporting subsidiary, DJO Finance LLC ("DJOFL"), for the first quarter ended March 30, 2013.

26 Apr 2013

Scioderm completes Series A financing commitment totaling $16 million

Scioderm, a company developing novel dermatology therapeutics, today announced the completion of a Series A financing commitment totaling $16 million. Morgenthaler Ventures led the Series A financing, with Technology Partners as the second investor participating in the round.

26 Apr 2013